has entered into an agreement with AstraZeneca
for its OX-CLI preclinical program for the potential treatment of respiratory diseases. AZ has been granted rights to conduct further preclinical research and evaluation of compounds in Orexo’s OX-CLI program. AZ also has an option to acquire the compounds, subject to a full asset transfer agreement, under which Orexo will receive development milestones and royalties on future revenues. Financial terms were not disclosed.
“Our OX-CLI program is a promising R&D project, which has potential to improve the treatment of respiratory diseases for millions of patients. AstraZeneca, a leading global company within the inflammatory and respiratory area, is the optimal partner for OX-CLI and we look forward to see the project advancing,” said chief executive officer Anders Lundström.